NCT05713123 Comparison of Record in VERITON Camera to the Anger Camera Procedure in Patients Treated by 131-iodine
| NCT ID | NCT05713123 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Device |
| Study Type | INTERVENTIONAL |
| Enrollment | 77 participants |
| Start Date | 2022-12-26 |
| Primary Completion | 2024-12-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 77 participants in total. It began in 2022-12-26 with a primary completion date of 2024-12-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to show that the SPECT/CT whole body recording procedure lasting less than or equal to 30 minutes in a VERITON-CT™ camera, can be substituted for the classic procedure, giving at least equivalent information in searches for primary or metastatic neoplastic lesions.
Eligibility Criteria
Inclusion Criteria: 1. Patients over the age of 18, who have understood and signed the informed consent form. 2. Person suffering from thyroid cancer and for whom the multidisciplinary meeting has validated a treatment by iodine 131 (1100 MBq or 3700 MBq). 3. Person with no contraindication to carrying out the examination. 4. Person affiliated to a social security scheme. Exclusion Criteria: 1. Person with a known allergy to one of the components of the radiopharmaceutical (Iodine 131 capsule). 2. Pregnant woman or woman of childbearing age and without suitable contraceptive means, or breastfeeding mother. 3. Person whose medical condition is unstable and/or unable to remain still in the supine position during recordings. 4. Person deprived of liberty by a judicial or administrative decision. 5. Person of full age subject to a measure of legal protection (guardianship, curators, safeguard of justice). 6. Adult person unable to express his consent and who is not the subject of a legal p
Frequently Asked Questions
Who can join the NCT05713123 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Device. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05713123 currently recruiting?
Yes, NCT05713123 is actively recruiting participants. Visit ClinicalTrials.gov or contact Central Hospital, Nancy, France to inquire about joining.
Where is the NCT05713123 trial being conducted?
This trial is being conducted at Vandœuvre-lès-Nancy, France.
Who is sponsoring the NCT05713123 clinical trial?
NCT05713123 is sponsored by Central Hospital, Nancy, France. The trial plans to enroll 77 participants.